Novartis Q3 Preview: Zolgensma Back In The Spotlight
First sales of SMA gene therapy to be revealed
Executive Summary
Analysts will be keen to hear about the launches of key new drugs Zolgensma and Mayzent as they ponder how long sales of Cosentyx can keep climbing.